@article{80e499cd8d524ae5883d939444727242,
title = "Immunogenicity of subcutaneous TNF inhibitors and its clinical significance in real-life setting in patients with spondyloarthritis",
keywords = "Spondyloarthritis, Ankylosing spondylitis, Biological therapy, Anti-drug antibodies, Disease activity, Therapeutic drug monitoring, MODIFYING ANTIRHEUMATIC DRUGS, LONG-TERM TREATMENT, ANKYLOSING-SPONDYLITIS, RHEUMATOID-ARTHRITIS, ANTIDRUG ANTIBODIES, DISEASE-ACTIVITY, INFLIXIMAB TREATMENT, CERTOLIZUMAB PEGOL, ALPHA BLOCKERS, DOUBLE-BLIND, 3121 General medicine, internal medicine and other clinical medicine",
author = "{FinADASpA Study Grp} and J. Hiltunen and P. Parmanne and T. Sokka and T. Lamberg and P. Isom{\"a}ki and O. Kaipiainen-Sepp{\"a}nen and R. Peltomaa and T. Uutela and L. Pirila and K. Taimen and Kauppi, {M. J.} and T. Yli-Kerttula and R. Tuompo and H. Relas and S. Kortelainen and K. Paalanen and J. Asikainen and P. Ekman and A. Santisteban and K-L Vidqvist and K. Tadesse and M. Romu and J. Borodina and P. Elfving and H. Valleala and M. Leirisalo-Repo and Minna Rantalaiho and H. Kautiainen and Jokiranta, {T. S.} and Eklund, {K. K.}",
year = "2022",
doi = "10.1007/s00296-021-04955-8",
language = "English",
volume = "42",
pages = "1015–1025",
journal = "Rheumatology International",
issn = "0172-8172",
publisher = "Springer Science and Business Media Deutschland GmbH",
}